Vor Biopharma, Inc. VOR 深 滬
等待開盤 09-30 09:30:00 美东时间
39.89
+6.270
+18.65%
華盛通- 最 高40.21
- 今 開34.11
- 成交量 57.72万股
- 最 低 34.11
- 昨 收 33.62
- 總市值 2.73亿
- 52周最高 65.80
- 市盈率 靜 --
- 換手率 8.44%
- 52周最低 2.622
- 委 比 -20.96%
- 總股本 684.11万
- 歷史最高 1272.40
- 量 比 1.55
- 振 幅 18.14%
- 歷史最低 2.622
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
Vor Bio announced that Phase 3 clinical data for telitacicept in treating primary Sjögren’s disease in China will be presented at ACR Convergence 2025 as a late-breaking poster. The presentation, titled "Efficacy and Safety of Telitacicept in Patients with Sjögren's Disease," will occur on October 28, 2025, in Chicago. RemeGen submitted a BLA for telitacicept in China, seeking approval for primary Sjögren’s disease, which would be its fourth indi...
09-29 11:00
Vor Biopharma Files For Offering Of Up To 51.0M Common Shares By The Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1817229/000119312525215602/d56908ds3.htm
09-25 05:02
Vor Biopharma Announces 1-for-20 Reverse Stock Split
The latest update is out from Vor Biopharma ( ($VOR) ). On September 17, 2025, ...
09-17 21:32
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
Vor Bio announced that 48-week data from a Phase 3 study of telitacicept for generalized myasthenia gravis (gMG) in China will be presented at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting in October 2025. The study, sponsored by collaborator RemeGen Co., Ltd, highlights telitacicept's efficacy and safety in reducing autoantibodies and improving symptoms in gMG patients. Telitacicept is approved in China fo...
09-17 20:15
Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
<p>Vor Bio, a clinical-stage biotechnology company focused on autoimmune diseases, announced its participation in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025. The event will also include virtual 1x1 investor meetings. A live webcast and replay of the fireside chat will be available on the Company’s website at [https://ir.vorbio.com/events-presentations/](https://ir.vorbio.com/events-presentat...
09-12 20:15
从甲骨文看科技股投资要点，中港红利债券为啥走势分化？
（来源：基少成多） 美股的甲骨文昨天传出了一个利空与一个利好，直接带火了尚在下跌中的AI产业链： 利空是最新的季报显示，营收增12%至149亿美元，净利润下滑...
09-11 08:15
Vor Biopharma Focuses on Telitacicept Development Strategy
An announcement from Vor Biopharma ( ($VOR) ) is now available. Vor Biopharma I...
09-02 22:57
东海研究 | 晨会纪要20250901
（来源：东海研究） 证券分析师： 张季恺，执业证书编号：S0630521110001 王洋，执业证书编号：S0630513040002 联系人: 李嘉豪...
09-01 16:47
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing.
08-28 01:21
Vor Biopharma Appoints Sarah Reed to Board
Vor Biopharma ( ($VOR) ) has issued an update. Vor Biopharma recently experienc...
08-28 00:57
